Moderna closed at $174.38, up about 177% in one session - market cap went from roughly $25B to $69B, on volume around 19x its three-month average.
The trigger: the Phase 3 INTerpath-001 trial of its individualised mRNA cancer therapy with Merck's KEYTRUDA met its primary endpoint in resected melanoma, the first late-stage win for this approach. Merck rose about 11% to a 52-week high.
→ Why it moved: https://marketchacha.com/movers
This article is for educational and informational purposes only. It is not financial advice, investment recommendation, or a solicitation to buy or sell securities. Investing involves significant risks. I am not a SEBI-registered investment advisor. Readers should consult their own financial advisor and conduct their own research before making any investment decisions.
Comments
Join the conversation
Sign in to join the conversation.
Follow replies, add your view, and take part in the discussion.
Sign in to commentLoading comments...